SCHEDULE: BlackRock Reports 5.7% Stake in Mirum Pharmaceuticals

BlackRock Inc. has disclosed a beneficial ownership of 5.7% in Mirum Pharmaceuticals, Inc. as of March 31, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Mirum Pharmaceuticals, Inc. common stock.
• As of March 31, 2026, BlackRock beneficially owns 3,465,559 shares, representing 5.7% of the class of securities.
• The filing specifies that BlackRock has sole voting power over 3,404,101 shares and sole dispositive power over 3,465,559 shares.
• No single person's interest in the common stock of Mirum Pharmaceuticals, Inc. exceeds five percent of the total outstanding common shares, according to the filing.
• The filing is an amendment to a previous filing and is made in accordance with SEC Release No. 34-39538.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of institutional ownership and does not provide new operational or financial information about the company itself.

Positives

• BlackRock's investment indicates confidence in Mirum Pharmaceuticals, Inc. from a major institutional investor.
• The disclosure of a significant stake by a large asset manager can sometimes lead to increased investor interest.

Negatives

• The filing is a routine disclosure for a significant institutional holding and does not inherently contain negative financial or operational news about Mirum Pharmaceuticals, Inc.

Risks

• The filing does not explicitly mention any risks related to Mirum Pharmaceuticals, Inc. itself, but BlackRock's investment is subject to market risks inherent in the pharmaceutical sector.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Mirum Pharmaceuticals, Inc.

Industry Context

StockSavvy.ai notes that institutional ownership filings like this Schedule 13G are common for publicly traded companies. BlackRock's significant stake suggests it views Mirum Pharmaceuticals, Inc. as a potentially valuable investment within the biotechnology and pharmaceutical sector, a sector characterized by innovation, regulatory hurdles, and significant capital requirements.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively by some shareholders as a sign of confidence, but it does not directly alter current share value or rights.
• Management and Employees: The filing does not directly impact management or employees, but sustained institutional interest can indirectly support company growth initiatives.
• Creditors: No direct impact on creditors is indicated by this ownership disclosure.

Next Steps

• BlackRock will continue to monitor its investment in Mirum Pharmaceuticals, Inc.
• Mirum Pharmaceuticals, Inc. will continue its business operations and regulatory disclosures.

Key Dates

Keywords

Schedule 13G, BlackRock, Mirum Pharmaceuticals, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Securities Exchange Act